NCT03511391 CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors Status COMPLETED Phase PHASE2
NCT03504696 Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced Melanoma Status COMPLETED Phase N/A
NCT03504488 CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) Status COMPLETED Phase PHASE1/PHASE2
NCT03501368 Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma Status COMPLETED Phase PHASE1
NCT03484923 Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma Status COMPLETED Phase PHASE2
NCT03480152 Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer Status TERMINATED Phase PHASE1/PHASE2
NCT03472027 Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma Status COMPLETED Phase PHASE1
NCT03470922 A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma Status ACTIVE_NOT_RECRUITING Phase PHASE2/PHASE3
NCT03455764 MCS110 With BRAF/MEK Inhibition in Patients With Melanoma Status COMPLETED Phase PHASE1/PHASE2
NCT03454919 Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations Status UNKNOWN Phase PHASE2
NCT03454035 Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors Status RECRUITING Phase PHASE1
NCT03452774 SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry Status RECRUITING Phase N/A
NCT03448497 Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom Status COMPLETED Phase N/A
NCT03438279 Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy Status COMPLETED Phase N/A
NCT03435640 REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies Status TERMINATED Phase PHASE1/PHASE2